Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.
about
Gastric biomarkers: a global reviewAdjuvant therapy for gastric cancer: what have we learned since INT0116?Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncologyClinical impact of tumour biology in the management of gastroesophageal cancerImpact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.Carbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma.Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma.Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapiesThe coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study.FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre studyHER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma.Emerging tyrosine kinase inhibitors for esophageal cancer.HER2 therapies and gastric cancer: a step forward.Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?Endoscopic biopsies from gastrointestinal carcinomas and their suitability for molecular analysis: a review of the literature and recommendations for clinical practice and research.Emerging mAbs for the treatment of esophagogastric cancer.Update on Gastroesophageal Adenocarcinoma Targeted Therapies.Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.Novel Targeted Therapies for Esophagogastric Cancer.Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma.Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis.HER2 in resected gastric cancer: Is there prognostic value?Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis.Met, IGF1R, and other new targets in upper GI malignancies.Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer.High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection.HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial).Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study.Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions.DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells
P2860
Q26741859-35EF7E59-99FA-4294-A838-4B8BF8F7B7D3Q27008675-72A10318-2E51-4826-B6D8-00E6F687FC12Q28085398-8A67EC28-31E6-4129-B39C-3E13209220FDQ33922534-8F32B473-FB86-49AD-AAAB-C815F36B0194Q35878616-EA6F5ABA-1FCA-46FB-91EB-35D2E1010401Q36358540-87F8B9ED-2A6E-45D0-ADEB-7B0AED91F25FQ36666667-910AE61B-2D71-4CE1-9F29-422E0766BA0EQ37241496-537E37AE-A617-4C1C-A7D9-44FFA712BF45Q37302936-4D3B761F-2280-4150-BF00-C611A05536E1Q37594375-6B6D956B-6337-404F-A0ED-224DDB1DAC3CQ37599574-AE447E91-EB57-4048-9BFB-DCBC3E1402EEQ38110962-AC607D02-75F0-4B0F-9985-3D577E0B9E84Q38151672-6F1F57DC-9B6C-4CD3-9876-33FFCC9632DBQ38184380-4DE3F87C-FCEF-4319-8F0A-B690E1B120DDQ38272251-F2CF7DF9-D977-43A4-B69E-2ED494D0758EQ38284597-C0C1810B-285E-4699-81E4-B5DCA48EAA2BQ38684349-269835E0-0410-4332-BBEE-1A7B063EECB8Q39038837-B735E72C-1841-432D-869C-04DB7C82B202Q39080349-AA5F2182-DD65-4415-8DD2-3E41D92616EAQ39171565-EBC6CE5B-71A5-4A33-99FC-FDE1F007001FQ39751816-9BEBCD01-8561-4EEF-BDC7-0DBBFA98E15EQ40619773-83233AEE-B755-42E8-B91F-8841CB230B0CQ41069109-7E478659-01B1-40A8-BD75-24D59DF2C649Q43479667-29BEF846-D844-4909-8F92-4F853FB1D8D7Q44578051-9793AEC6-937E-4DCB-B929-5B6BED5AC550Q47764668-9BEC012D-E682-4ED3-B2A4-E16484258229Q47967299-C6921B5F-8214-415A-BDC1-77386D24B9C3Q48379063-97A514BE-A271-4B78-BD53-479BA427B0E4Q51762437-0B0F624C-1F10-4EC0-AFA5-8D926488E491Q54340137-C0AD0537-4855-4720-9DCF-290B83C09C56Q54784542-88D1FAE8-51AE-4C25-B661-06334F4FA4FAQ55654316-C2FA16A1-6D4F-4D3E-AE55-443E2008F761Q57753663-791B1697-837E-499D-B63E-9A79E7604A06
P2860
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Effect of HER2 on prognosis an ...... ocarcinoma in the MAGIC trial.
@en
Effect of HER2 on prognosis an ...... ocarcinoma in the MAGIC trial.
@nl
type
label
Effect of HER2 on prognosis an ...... ocarcinoma in the MAGIC trial.
@en
Effect of HER2 on prognosis an ...... ocarcinoma in the MAGIC trial.
@nl
prefLabel
Effect of HER2 on prognosis an ...... ocarcinoma in the MAGIC trial.
@en
Effect of HER2 on prognosis an ...... ocarcinoma in the MAGIC trial.
@nl
P2093
P2860
P356
P1433
P1476
Effect of HER2 on prognosis an ...... ocarcinoma in the MAGIC trial.
@en
P2093
A F C Okines
A Wotherspoon
J S Reis-Filho
L C Thompson
R E Langley
S Stenning
T S Waddell
P2860
P304
P356
10.1093/ANNONC/MDS622
P577
2012-12-11T00:00:00Z